BMS’s dual lipid kinase inhibitor; plus prime editing in NHPs and more

In a Science Translational Medicine study,  Bristol Myers Squibb Co. (NYSE:BMY) reported discovery of a dual DGKA/DGKZ inhibitor, BMS-684, and optimization of an analog, BMS-502, that synergized with anti-PD-1 therapy to inhibit tumors in syngeneic mouse models of colorectal cancer.

Insilico Medicine Inc. has DGKA inhibitor ISM4312A in preclinical development for solid tumors, and Astellas Pharma Inc. (Tokyo:4503) has DGKZ inhibitor ASP1570 in a Phase I/II trial for solid tumors...